Investing.com - 诺华 (SIX:NOVN)周一股价上涨2.2%,此前这家制药巨头宣布其用于治疗成人活动性Sjögren综合征的ianalumab在两项三期临床试验中取得积极的初步结果。 该公司报告称,NEPTUNUS-1和NEPTUNUS-2试验均达到了主要终点,显示疾病活动性有统计学意义的显著改善。 这是首次在全球三期临床试验中显示Sjögren综合征治疗改善的案例,使...
Source LinkInvesting.com - 诺华 (SIX:NOVN)周一股价上涨2.2%,此前这家制药巨头宣布其用于治疗成人活动性Sjögren综合征的ianalumab在两项三期临床试验中取得积极的初步结果。 该公司报告称,NEPTUNUS-1和NEPTUNUS-2试验均达到了主要终点,显示疾病活动性有统计学意义的显著改善。 这是首次在全球三期临床试验中显示Sjögren综合征治疗改善的案例,使...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.